MERIDIAN THERAPEUTICS

Emrelimab

PRODUCT INFORMATION · International

This document is fictional and is provided for demonstration purposes only.
It is not real prescribing information and must not be used to inform clinical decisions.
Intended for healthcare professionals.

1. INDICATION

Emrelimab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Approval status and approved conditions of use vary between territories. Use in adolescents is not approved in all territories. This information should be read together with the product information approved locally.

2. DOSAGE AND ADMINISTRATION

The recommended dose in adults is 300 mg administered by subcutaneous injection at weeks 0 and 4, and every 12 weeks thereafter.

Locally approved dosing recommendations take precedence where these differ from the information presented here. Prescribers should consult the product information approved in their territory before prescribing.

3. IMPORTANT SAFETY INFORMATION

Emrelimab is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, and in patients with clinically important active infection, including active tuberculosis.

Emrelimab may increase the risk of infection. Patients should be evaluated for tuberculosis infection prior to initiating treatment and monitored for signs and symptoms of infection during treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported.

The most frequently reported undesirable effects were upper respiratory tract infections, headache and injection site reactions.

The safety information presented here is abbreviated and may not reflect the labelling approved in your territory. The locally approved product information should be consulted in all cases.

4. REPORTING OF SUSPECTED ADVERSE REACTIONS

To report a suspected adverse reaction, contact Meridian Therapeutics Drug Safety on +44 20 7946 0318 or safety.intl@meridiantx.example. Suspected adverse reactions should also be reported in accordance with local requirements.

5. APPROVAL RECORD

Job code..... ROW-EMR-2026-0056
Market..... International
Date of preparation... September 2026
Review date..... June 2027